{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:51Z","timestamp":1786998471928,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ygyno.2019.07.020","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T07:20:58Z","timestamp":1565421658000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology\/Gynecologic Oncology Group ancillary data analysis of GOG 218"],"prefix":"10.1016","volume":"155","author":[{"given":"K.N. Slaughter","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-0966","authenticated-orcid":false,"given":"R.","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-7000","authenticated-orcid":false,"given":"K.S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Bakkum-Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Bookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.07.020_bb0005","article-title":"Cancer statistics, 2018","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"18","key":"10.1016\/j.ygyno.2019.07.020_bb0010","article-title":"Phase III trial of BEV (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study","volume":"28","author":"Burger","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0015","unstructured":"Perren T, Swart AM, Pfisterer J, et al. ICON7: a phase III randomised gynaecologic cancer intergroup trial of concurrent BEV and chemotherapy followed by maintenance BEV, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann. Oncol. 21 (201) viii2-viii3."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"381","author":"Reneham","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0030","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/sj.ijo.0802987","article-title":"Angiogenic factors are elevated in overweight and obese individuals","volume":"29","author":"Silha","year":"2005","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0035","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00125-003-1221-6","article-title":"Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects","volume":"46","author":"Miyazawe-Hoshimoto","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0040","first-page":"437","article-title":"A novel technique for the determination of body fat by computed tomography","volume":"7","author":"Tokunaga","year":"1983","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1148\/radiology.211.1.r99ap15283","article-title":"Abdominal fat: standardized technique for measurement at CT","volume":"211","author":"Yoshizumi","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0050","first-page":"32","article-title":"Not all fat is equal differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer","volume":"22","author":"Modesitt","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0055","first-page":"88","article-title":"Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues","volume":"1500","author":"Dusserre","year":"2000","journal-title":"Biochem. Biophys. Acta"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0060","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.2009.188946","article-title":"Visceral fat area is an independent predictive biomarker of outcome after first-line BEV-based treatment in metastatic colorectal cancer","volume":"59","author":"Guiu","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0065","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.ejca.2011.06.038","article-title":"Influence of body mass index on outcomes in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy","volume":"47","author":"Simkens","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1634\/theoncologist.2010-0227","article-title":"Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents","volume":"16","author":"Ladoire","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0075","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Xie W, Kollmannsberger CK, et al. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration [abstract 4524]. Presented at the 2010 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 4\u20138, 2010.","DOI":"10.1200\/jco.2010.28.15_suppl.4524"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0080","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1634\/theoncologist.2011-0213","article-title":"Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor \u2014 targeted therapy?","volume":"16","author":"Steffens","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2014.01.031","article-title":"Measurements of adiposity as clinical biomarkers for first-line BEV-based chemotherapy in epithelial ovarian cancer","volume":"133","author":"Slaughter","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0090","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/ajcn\/81.6.1330","article-title":"Waist circumference and abdominal adipose tissue distribution: influence of age and sex","volume":"81","author":"Kuk","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0095","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1245\/s10434-008-9891-4","article-title":"Visceral obesity may affect oncologic outcome in patients with colorectal cancer","volume":"15","author":"Moon","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0100","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jamcollsurg.2013.01.007","article-title":"Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation","volume":"216","author":"Clark","year":"2013","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0105","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0110","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1073\/pnas.0308671100","article-title":"Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis","volume":"101","author":"Brakenhielm","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.07.020_bb0115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2019.07.020_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jb\/mvs128","article-title":"The vasohibin family: a novel family for angiogenesis regulation","volume":"153","author":"Sato","year":"2013","journal-title":"J. Biochem."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581931409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581931409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:46:09Z","timestamp":1758771969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581931409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S009082581931409X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.07.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology\/Gynecologic Oncology Group ancillary data analysis of GOG 218","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}